Evidence map›Paper›PMID 41999663›Full record

ArticleCancer discovery2026

Spatial Integration of Protein and Chromosomal States Reveals Early Copy-Number Changes and Genotype-Associated Immune Neighborhoods in Serous Ovarian Cancer Evolution.

Tanjina Kader, Yu-An Chen, Clemens B Hug, Jia-Ren Lin, Jeremy L Muhlich, Shannon Coy, Euihye Jung, Lauren E Schwartz, Thomas Fazio, Crystal Chiu and 5 more

Abstract read
In one paragraph

Article in Cancer discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Tanjina KaderLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-1463-7593
Yu-An ChenLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0001-7228-4696
Clemens B HugLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-8299-3274
Jia-Ren LinLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-4702-7705
Jeremy L MuhlichLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-0811-637X
Shannon CoyLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0003-0033-9031
Euihye JungPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0003-1202-247X
Lauren E SchwartzPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0003-2418-7167
Thomas FazioPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0009-0004-5655-0180
Crystal ChiuLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0005-6362-494X
Scott T RyallDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.ORCID 0009-0005-8371-4731
Charles W DrescherPaul G. Allen Research Center at Providence-Swedish Cancer Institute, Seattle, Washington.ORCID 0000-0002-6579-0416
Peter K SorgerLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-3364-1838
Ronny DrapkinPenn Ovarian Cancer Research Center, Department of Obstetrics and Gynecology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.ORCID 0000-0002-6912-6977
Sandro SantagataLaboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-7528-9668

Funding

Advancing technologies for the collection and analysis of high dimensional immunoprofiles and tumor imagesR50CA274277 · NCI · HARVARD MEDICAL SCHOOL · PI Jia-Ren Lin · 2022 to 2026
$879k
Canary Foundation (THE CANARY FUND)Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF)Goldsmith Ovarian Cancer Translational Research FundGray FoundationLudwig Center at Harvard (Ludwig Center)National Institutes of Health (NIH) R50-CA274277NCI NIH HHS R50 CA274277U.S. Department of Defense (DOD) W81XWH-22-1-0852
6 · The paper itself

Abstract

Detecting chromosomal copy-number alterations together with protein-defined cell states in intact tissue is critical for understanding early clonal evolution and microenvironmental interactions in cancer. We developed ORION-FISH, which integrates high-plex tissue imaging with a morphology-preserving DNA fluorescence in situ hybridization (DNA-FISH) workflow and single-cell registration, yielding measurements concordant with clinical FISH. In high-grade serous ovarian carcinoma (HGSOC), ORION-FISH recapitulated known chromosomal changes while revealing subclonal heterogeneity missed by targeted sequencing. Applied to serous tubal intraepithelial carcinomas, precursors of HGSOC, ORION-FISH identified intermixed epithelial cells with MYC or CCNE1 copy-number gains, as well as concurrent alterations associated with distinct immune microenvironments. In addition, epithelial cells with MYC and CCNE1 copy-number gains were detected in morphologically normal fallopian tube epithelium, along with rare MDM4 increases across epithelial lineages. Together, ORION-FISH provides a framework linking chromosomal copy-number states to protein-defined phenotypes within preserved tissue architecture, enabling context-aware interrogation of early copy-number diversification at single-cell resolution. SIGNIFICANCE: We introduce ORION-FISH, a spatially resolved workflow integrating multiplexed protein imaging with DNA-FISH to map genomic alterations within intact tissues. Applying this approach to ovarian cancer precursors reveals early copy-number diversification and associations with the local immune context, providing a foundation for studying how genomic and microenvironmental states coevolve during tumor initiation.

Indexed as

Cystadenocarcinoma, SerousDNA Copy Number VariationsOvarian NeoplasmsFemaleGenotypeHumansIn Situ Hybridization, FluorescenceTumor Microenvironment

Identifiers

PMID41999663
PMCPMC13530990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.